Major Pharmaceuticals has initiated a nationwide voluntary recall of levothyroxine sodium tablets, citing potential subpotency concerns.
The recall, announced on July 13, 2026, covers multiple strengths and lot numbers.
>>> Canadiens in Active Trade Talks with Blue Jackets for Center
The action involves twelve product lines across seven dosage strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg, and 150 mcg.
All affected tablets were packaged in unit dose blister cartons and distributed from Indianapolis.
Why the Recall Matters
Levothyroxine sodium is a synthetic thyroid hormone used to treat hypothyroidism, a condition where the thyroid gland does not produce enough hormones.
Subpotent medication may leave patients undertreated, potentially worsening symptoms such as fatigue, weight gain, cold sensitivity, and cognitive issues.
The U. S.
>>> Madison Leaders Withdraw Amendments to End Police Oversight Dispute
Food and Drug Administration has classified the recall as Class II.
This means that using the product may cause temporary or medically reversible health problems, while the risk of serious harm is low.
No formal press release has been issued by the company, but notification letters have been sent to consignees and the public.
Patients are advised to check lot numbers on their packaging and consult a healthcare provider or pharmacist if they have concerns.
>>> US Agency Expands Medical Surveillance Amid Global Hospital Projects
Distributing facilities must quarantine any affected inventory.
